Multimodal fusion of radio-pathology and proteogenomics identify integrated glioma subtypes with prognostic and therapeutic opportunities
Zaoqu Liu,
Yushuai Wu,
Hui Xu,
Minkai Wang,
Siyuan Weng,
Dongling Pei,
Shuang Chen,
WeiWei Wang,
Jing Yan,
Li Cui,
Jingxian Duan,
Yuanshen Zhao,
Zilong Wang,
Zeyu Ma,
Ran Li,
Wenchao Duan,
Yuning Qiu,
Dingyuan Su,
Sen Li,
Haoran Liu,
Wenyuan Li,
Caoyuan Ma,
Miaomiao Yu,
Yinhui Yu,
Te Chen,
Jing Fu,
YingWei Zhen,
Bin Yu,
Yuchen Ji,
Hairong Zheng,
Dong Liang,
Xianzhi Liu,
Dongming Yan,
Xinwei Han (),
Fubing Wang (),
Zhi-Cheng Li () and
Zhenyu Zhang ()
Additional contact information
Zaoqu Liu: The First Affiliated Hospital of Zhengzhou University
Yushuai Wu: Shanghai Academy of Artificial Intelligence for Science
Hui Xu: The First Affiliated Hospital of Zhengzhou University
Minkai Wang: The First Affiliated Hospital of Zhengzhou University
Siyuan Weng: The First Affiliated Hospital of Zhengzhou University
Dongling Pei: The First Affiliated Hospital of Zhengzhou University
Shuang Chen: The First Affiliated Hospital of Zhengzhou University
WeiWei Wang: The First Affiliated Hospital of Zhengzhou University
Jing Yan: The First Affiliated Hospital of Zhengzhou University
Li Cui: The First Affiliated Hospital of Zhengzhou University
Jingxian Duan: Chinese Academy of Sciences
Yuanshen Zhao: Chinese Academy of Sciences
Zilong Wang: The First Affiliated Hospital of Zhengzhou University
Zeyu Ma: The First Affiliated Hospital of Zhengzhou University
Ran Li: Hangzhou City University
Wenchao Duan: The First Affiliated Hospital of Zhengzhou University
Yuning Qiu: The First Affiliated Hospital of Zhengzhou University
Dingyuan Su: The First Affiliated Hospital of Zhengzhou University
Sen Li: The First Affiliated Hospital of Zhengzhou University
Haoran Liu: The First Affiliated Hospital of Zhengzhou University
Wenyuan Li: The First Affiliated Hospital of Zhengzhou University
Caoyuan Ma: The First Affiliated Hospital of Zhengzhou University
Miaomiao Yu: The First Affiliated Hospital of Zhengzhou University
Yinhui Yu: The First Affiliated Hospital of Zhengzhou University
Te Chen: The First Affiliated Hospital of Zhengzhou University
Jing Fu: The First Affiliated Hospital of Zhengzhou University
YingWei Zhen: The First Affiliated Hospital of Zhengzhou University
Bin Yu: The First Affiliated Hospital of Zhengzhou University
Yuchen Ji: The First Affiliated Hospital of Zhengzhou University
Hairong Zheng: Chinese Academy of Sciences
Dong Liang: Chinese Academy of Sciences
Xianzhi Liu: The First Affiliated Hospital of Zhengzhou University
Dongming Yan: The First Affiliated Hospital of Zhengzhou University
Xinwei Han: The First Affiliated Hospital of Zhengzhou University
Fubing Wang: Zhongnan Hospital of Wuhan University
Zhi-Cheng Li: Chinese Academy of Sciences
Zhenyu Zhang: The First Affiliated Hospital of Zhengzhou University
Nature Communications, 2025, vol. 16, issue 1, 1-18
Abstract:
Abstract Integrating multimodal data can uncover causal features hidden in single-modality analyses, offering a comprehensive understanding of disease complexity. This study introduces a multimodal fusion subtyping (MOFS) framework that integrates radiological, pathological, genomic, transcriptomic, and proteomic data from 122 patients with IDH-wildtype adult glioma, identifying three subtypes: MOFS1 (proneural) with favorable prognosis, elevated neurodevelopmental activity, and abundant neurocyte infiltration; MOFS2 (proliferative) with the worst prognosis, superior proliferative activity, and genome instability; MOFS3 (TME-rich) with intermediate prognosis, abundant immune and stromal components, and sensitive to anti-PD-1 immunotherapy. STRAP emerges as a prognostic biomarker and potential therapeutic target for MOFS2, associated with its proliferative phenotype. Stromal infiltration in MOFS3 serves as a crucial prognostic indicator, allowing for further prognostic stratification. Additionally, we develop a deep neural network (DNN) classifier based on radiological features to further enhance the clinical translatability, providing a non-invasive tool for predicting MOFS subtypes. Overall, these findings highlight the potential of multimodal fusion in improving the classification, prognostic accuracy, and precision therapy of IDH-wildtype glioma, offering an avenue for personalized management.
Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:
Downloads: (external link)
https://www.nature.com/articles/s41467-025-58675-9 Abstract (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58675-9
Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/
DOI: 10.1038/s41467-025-58675-9
Access Statistics for this article
Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie
More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().